Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children Wit

This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years.

Study Overview

• Status: Completed
• Conditions: Attention Deficit Hyperactivity Disorder
• Intervention / Treatment: Drug: amphetamine extended-release oral suspension, 2.5 mg/mL; Drug: Placebo extended-release oral suspension

Detailed Description

This is a randomized, double-blind, two treatment, two sequence, placebo-controlled crossover study to assess the efficacy and safety of dose Dyanavel XR in reducing signs and symptoms of ADHD compared with placebo in pediatric subjects ages 6 to 12 years with ADHD.

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Nevada
    • Las Vegas, Nevada, United States, 89128
      • Center for Psychiatry and Behavioral Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 12 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Males or females aged 6 to 12 years at the time of screening, inclusive
2. Diagnosed with ADHD by a psychiatrist within 6 months of study enrolment or newly diagnosed with ADHD using the DSM-5 criteria for ADHD

3. An ADHD-RS-5 score at Screening ≥90th percentile for sex and age in at least one of the following categories:

   1. Hyperactive-impulsive subscale,
   2. Inattentive subscale, or
   3. Total score. Subjects who do not meet this criteria at screening can have ADHD-RS-5 repeated at baseline, after washout of stimulant medication for a minimum of 24 hours prior to baseline.
4. In the clinical judgment of the Investigator, the subject must be in need of pharmacological treatment for ADHD.
5. Females of childbearing potential must be non-lactating and must have a negative serum pregnancy test at screening
6. Provide written informed consent (parent/guardian) and assent (child aged 10 - 12 years only) prior to participation in the study

Exclusion Criteria:

1. Diagnosed with any DSM-5 active disorder (other than ADHD) with the exception of specific phobias, learning disorders, motor skills disorders, communication disorders, oppositional defiant disorder, elimination disorders, and sleep disorders
2. Known history of chronic medical illnesses including severe hypertension, untreated thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy, known family history of sudden death
3. Known history or presence of significant renal or hepatic disease, as indicated by clinical laboratory assessment (liver function test results ≥ two times the upper limit of normal, blood urea nitrogen, or creatinine).
4. Clinically significant abnormal ECG or cardiac findings on physical examination (including the presence of a pathologic murmur)

5. Use of the following medications within 30 days of Baseline Visit:

   • MAOI - monoamine oxidase inhibitors (e.g., Selegiline, isocarboxazid, phenelzine, tranylcypromine)
   • Tricyclic Antidepressants (e.g. Desipramine, protriptyline)

6. Use of the following medications within 3 days of Baseline Visit

   • Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid)
   • Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts)
7. Use of atomoxetine within 14 days of Baseline Visit
8. Planned use of prohibited drugs or agents from the Screening visit through the end of the study
9. Abnormal clinically significantly laboratory test value at screening that, in the opinion of the Investigator, would preclude study participation
10. Known history of allergy/hypersensitivity to amphetamine or any of the components of Dyanavel XR, or topical anaesthetics
11. Known history of lack of response to amphetamine
12. Parent or guardian's inability or unwillingness to follow directions of the Investigator or study research staff.
13. Any uncontrolled medical condition that in the opinion of the Investigator would preclude study participation
14. History of significant illness requiring hospitalization, or surgery requiring anaesthetics within 30 days of Baseline Visit

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Active Treatment; Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM	Drug: amphetamine extended-release oral suspension, 2.5 mg/mL; 5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO; Other Names: Dyanavel XR; Drug: Placebo extended-release oral suspension; 6, 7 or 8 mL PO
Placebo Comparator: Placebo Treatment; Double blind placebo, 6, 7 or 8 mL po QAM	Drug: amphetamine extended-release oral suspension, 2.5 mg/mL; 5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO; Other Names: Dyanavel XR; Drug: Placebo extended-release oral suspension; 6, 7 or 8 mL PO

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose	Change in SKAMP-C (Swanson, Kotkin, Agler, M-Flynn, and Pelham combined) score from pre-dose, by treatment. The SKAMP-C is a rating scale that assesses functional impairment related to ADHD in the classroom, including the performance of academic tasks, following class rules, and interacting with peers and adults in the classroom. The SKAMP-C is a 13-item, 7-score rating system (0=normal to 7=maximal impairment). The higher the score, the worse the impairment. A decrease from baseline in the combined (all 13 items) score indicates improvement. The SKAMP-C is used to assess the time course of treatment effects in laboratory classroom studies.	Change in SKAMP-C score from baseline to 30 minutes postdose.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Permanent Product Measure of Performance (PERMP-C) Score (Problems Answered Correctly)	Change from pre-dose in PERMP-C scores (Permanent Product Measure of Performance; defined as the number of problems attempted and number of problems solved correctly) at 30 minutes post-dose and at 3 hours post-dose. The PERMP-C is designed to assess compliance and academic productivity in school children. It is a 10-minute timed test in which the number of problems attempted and correct are assessed prior to and after an intervention. Scoring is based on problems attempted and correct. An increase in numerical score is indicative of improvement.	30 minutes postdose and 3 hours postdose

Collaborators and Investigators

• Sponsor: Tris Pharma, Inc.
• Investigators: Study Chair: Sally Berry, MD, PhD, Tris Pharma

Publications and helpful links

General Publications

• Childress AC, Kando JC, King TR, Pardo A, Herman BK. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2019 Feb;29(1):2-8. doi: 10.1089/cap.2018.0078. Epub 2018 Dec 21.

Study record dates

Study Major Dates

• Study Start (Actual): February 11, 2017
• Primary Completion (Actual): February 25, 2017
• Study Completion (Actual): October 30, 2017

Study Registration Dates

• First Submitted: March 9, 2017
• First Submitted That Met QC Criteria: March 22, 2017
• First Posted (Actual): March 23, 2017

Study Record Updates

• Last Update Posted (Actual): July 22, 2019
• Last Update Submitted That Met QC Criteria: July 8, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Attention Deficit and Disruptive Behavior Disorders; Neurodevelopmental Disorders; Attention Deficit Disorder with Hyperactivity; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Dopamine Agents; Dopamine Uptake Inhibitors; Central Nervous System Stimulants; Sympathomimetics; Adrenergic Uptake Inhibitors; Amphetamine
• Other Study ID Numbers: TRI102-ADD-300

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No